Published 1 year ago

The Unbearable Cost of Drug Development: Deloitte Report Shows 15% Jump in R&D to $2.3 Billion

Summary by Ground News

The average cost of developing a new drug among the top 20 global biopharmas rose 15% last year, to approximately $2.3 billion. The return on investment for new drugs and vaccines plunged last year by 82%, to 1.2% from 10.1% in 2010. Deloitte counted 278 late-stage assets last year.

0 Articles

All

Left

Center

Right

GEN - Genetic Engineering and Biotechnology News…

The Unbearable Cost of Drug Development: Deloitte Report Shows 15% Jump in R&D to $2.3 Billion

A pair of recently-released studies shed new light on the staggering cost of developing new drugs—an expense that now exceeds $2 billion per therapy on average.

1 year ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.